Please use this identifier to cite or link to this item:
http://hdl.handle.net/10397/6304
Title: | Site-directed pegylation of arginases and the use thereof as anti-cancer and anti-viral agents | Authors: | Leung, TYC Lo, WHT |
Issue Date: | 13-Aug-2013 | Source: | US Patent 8,507,245 B2. Washington, DC: US Patent and Trademark Office, 2013. | Abstract: | Mono-pegylated arginase conjugate and method producing thereof. The mono-pegylated arginase is homogeneous in molecular weight and shows therapeutic effect for treating cancers and viral infections. The method of producing such arginase conjugate has a main step of genetically modifying the gene encoding an arginase so that the PEG moiety can attach to the enzyme at a predetermined, specific intended site. This is achieved by removing the PEG attaching amino acid residues at undesirable sites while keeping (or adding, if necessary) the one at the desirable site of the enzyme. Two exemplary mono-pegylated arginase conjugates so produced are human arginase I (HAI) where a polyethylene glycol (PEG) moiety is site-specific covalently bonded to Cys⁴⁵ of the enzyme and Bacillus caldovelox arginase (BCA) where a polyethylene glycol (PEG) moiety is site-specific covalently bonded to Cys¹⁶¹ of the enzyme. | Rights: | Assignee: The Hong Kong Polytechnic University. |
Appears in Collections: | Patent |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
us8507245b2.pdf | 2.88 MB | Adobe PDF | View/Open |
Page views
182
Last Week
0
0
Last month
Citations as of Apr 21, 2024
Downloads
69
Citations as of Apr 21, 2024
Google ScholarTM
Check
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.